MannKind Corporation
NASDAQ: MNKD0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael E. Castagna
- Employees
- 403
- Headquarters
- Danbury, United States
- IPO year
- 2004
- Market cap
- $1.2B
- Website
- https://www.mannkindcorp.com
Loading MNKD…
Loading profile data…Frequently asked questions about MNKD
What does MannKind Corporation (MNKD) do?
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glyc...
Where does MNKD trade?
MannKind Corporation (MNKD) trades on the NASDAQ Global Market.
What sector is MNKD in?
MannKind Corporation (MNKD) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of MannKind Corporation?
Michael E. Castagna is the chief executive officer of MannKind Corporation (MNKD).
Where is MannKind Corporation headquartered?
MannKind Corporation is headquartered in United States.
Does MNKD pay a dividend?
MannKind Corporation (MNKD) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MNKD go public?
MannKind Corporation (MNKD) completed its initial public offering in 2004.